CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Pfizer Purchase Agreement [Member]	Series A, B, C and D Convertible Preferred Stock [Member]	Common Stock [Member]	Common Stock [Member] Restricted Stock Units (RSUs) [Member]	Common Stock [Member] Pfizer Purchase Agreement [Member]	Additional Paid-in Capital [Member]	Additional Paid-in Capital [Member] Pfizer Purchase Agreement [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Income (Loss) [Member]
Balances at Dec. 31, 2020	$ 132,040		$ 3	$ 29			$ 409,722		$ (277,707)	$ (7)
Balances, Shares at Dec. 31, 2020			3,218,287	29,260,247
Issuance of common stock upon the exercise of stock options	1,218						1,218
Issuance of common stock upon the exercise of stock options, shares				135,571
Issuance of common stock, net of issuance costs	5,357	$ 27,289		$ 1		$ 2	5,356	$ 27,287
Issuance of common stock, net of issuance costs, shares				327,185		2,362,348
Conversion of convertible preferred stock to common stock, shares			(135)	135,000
Share-based compensation expense	6,502						6,502
Unrealized gain (loss) on available-for-sale securities	5									5
Net loss	(60,516)								(60,516)
Balances at Sep. 30, 2021	111,895		$ 3	$ 32			450,085		(338,223)	(2)
Balances, Shares at Sep. 30, 2021			3,218,152	32,220,351
Balances at Jun. 30, 2021	90,252		$ 3	$ 30			405,923		(315,702)	(2)
Balances, Shares at Jun. 30, 2021			3,218,152	29,699,147
Issuance of common stock upon the exercise of stock options	826						826
Issuance of common stock upon the exercise of stock options, shares				88,856
Issuance of common stock, net of issuance costs	1,105	$ 39,903				$ 2	1,105	$ 39,901
Issuance of common stock, net of issuance costs, shares				70,000		2,362,348
Share-based compensation expense	2,330						2,330
Unrealized gain (loss) on available-for-sale securities	0
Net loss	(22,521)								(22,521)
Balances at Sep. 30, 2021	111,895		$ 3	$ 32			450,085		(338,223)	(2)
Balances, Shares at Sep. 30, 2021			3,218,152	32,220,351
Balances at Dec. 31, 2021	88,289		$ 3	$ 32			455,719		(367,463)	(2)
Balances, Shares at Dec. 31, 2021			3,218,152	32,393,738
Issuance of common stock upon the exercise of stock options	$ 419						419
Issuance of common stock upon the exercise of stock options, shares	56,120			56,120
Issuance of common stock upon the vesting of RSUs, shares					75,287
Issuance of common stock, net of issuance costs	$ 10,331			$ 5			10,326
Issuance of common stock, net of issuance costs, shares				3,964,478
Conversion of convertible preferred stock to common stock	3		$ (3)	$ 6
Conversion of convertible preferred stock to common stock, shares			(3,218,152)	6,367,000
Share-based compensation expense	6,626						6,626
Unrealized gain (loss) on available-for-sale securities	2									$ 2
Net loss	(73,186)								(73,186)
Balances at Sep. 30, 2022	32,484			$ 43			473,090		(440,649)
Balances, Shares at Sep. 30, 2022				42,856,623
Balances at Jun. 30, 2022	35,923		$ 2	$ 35			464,860		(428,974)
Balances, Shares at Jun. 30, 2022			2,275,214	35,067,477
Issuance of common stock upon the vesting of RSUs, shares					75,287
Issuance of common stock, net of issuance costs	6,128			$ 4			6,124
Issuance of common stock, net of issuance costs, shares				3,226,859
Conversion of convertible preferred stock to common stock	2		$ (2)	$ 4
Conversion of convertible preferred stock to common stock, shares			(2,275,214)	4,487,000
Share-based compensation expense	2,106						2,106
Unrealized gain (loss) on available-for-sale securities	0
Net loss	(11,675)								(11,675)
Balances at Sep. 30, 2022	$ 32,484			$ 43			$ 473,090		$ (440,649)
Balances, Shares at Sep. 30, 2022				42,856,623